Swiss National Bank Takes $546,000 Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

Swiss National Bank bought a new position in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 18,900 shares of the company's stock, valued at approximately $546,000. Swiss National Bank owned 0.07% of LENZ Therapeutics at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of LENZ. Harbor Capital Advisors Inc. bought a new position in shares of LENZ Therapeutics in the fourth quarter worth approximately $1,270,000. Parkman Healthcare Partners LLC purchased a new position in LENZ Therapeutics in the 3rd quarter worth approximately $3,308,000. Barclays PLC grew its stake in LENZ Therapeutics by 273.1% in the 3rd quarter. Barclays PLC now owns 16,463 shares of the company's stock worth $391,000 after buying an additional 12,051 shares in the last quarter. The Manufacturers Life Insurance Company bought a new position in shares of LENZ Therapeutics in the 3rd quarter worth $743,000. Finally, Charles Schwab Investment Management Inc. raised its position in shares of LENZ Therapeutics by 197.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 123,371 shares of the company's stock valued at $2,929,000 after buying an additional 81,901 shares in the last quarter. 54.32% of the stock is currently owned by hedge funds and other institutional investors.

LENZ Therapeutics Stock Down 4.3 %

Shares of LENZ traded down $1.13 during trading hours on Wednesday, hitting $24.88. The company had a trading volume of 74,340 shares, compared to its average volume of 177,767. LENZ Therapeutics, Inc. has a 52-week low of $14.42 and a 52-week high of $38.93. The stock's 50 day moving average price is $24.62 and its 200 day moving average price is $27.25. The firm has a market cap of $685.27 million, a P/E ratio of -5.22 and a beta of 0.58.

Remove Ads

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.04). On average, research analysts expect that LENZ Therapeutics, Inc. will post -2.18 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. TD Cowen initiated coverage on shares of LENZ Therapeutics in a research report on Tuesday, March 18th. They issued a "buy" rating and a $60.00 target price for the company. Citigroup upped their price objective on LENZ Therapeutics from $44.00 to $47.00 and gave the stock a "buy" rating in a report on Thursday, March 20th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $41.67.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.